16:45 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Bridge's BBT-877 reduces lung fibrosis in mouse model of IPF

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said BBT-877 reduced lung fibrosis as measured by Ashcroft scores and deposition of collagen in a mouse model of bleomycin-induced idiopathic pulmonary fibrosis (IPF). Data were presented at the...
23:30 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis...
05:19 , Jun 16, 2017 |  BC Week In Review  |  Company News

LegoChem grants Bridge Biotherapeutics rights to autotaxin candidate

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said it received exclusive, worldwide rights to a small molecule inhibitor of autotaxin ( ENPP2 ; ATX) from LegoChem Biosciences Inc. (KOSDAQ:141080). LegoChem will receive KrW2 billion ($1.8 million)...